02/04/2020
‘Castle Creek Biosciences has received a $75 million investment to advance its gene therapy program.’
Castle Creek Biosciences has received a $75 million investment to advance its gene therapy program, including FCX-007, a treatment candidate for people with recessive dystrophic epidermolysis bullosa (RDEB) that now in a pivotal clinical trial. “We are proud to have the strategic support of...